General
Preferred name
VANDETANIB
Synonyms
Vandetanib (hydrochloride) ()
Vandetanib (trifluoroacetate) ()
ZD6474 hydrochloride ()
ZD6474 trifluoroacetate ()
Caprelsa, GNF-Pf-2188, Zactima, ZD-64, ZD-6474 ()
ZD6474 ()
Zactima ()
Caprelsa ()
ZD-6474 ()
Vandetanib (ZD6474) ()
V-9402 ()
GNF-PF-2188 ()
NSC-744325 ()
NSC-760766 ()
ZD-64 ()
Vandetanib hydrochloride ()
Vandetanib trifluoroacetate ()
Vandetanib-d6 ()
P&D ID
PD003329
CAS
443913-73-3
338992-00-0
524722-52-9
338992-53-3
1174683-49-8
Tags
obsolete probe
natural product
drug
available
Approved by
EMA
FDA
First approval
2011
Drug Status
approved
Drug indication
Solid tumour/cancer
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA ZD-6474 is a potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (REarranged during Transfection) tyrosine kinases. ; ; VEGFR- and EGFR-dependent signalling are both clinically validated pathways in cancer, including non-small-cell lung cancer (NSCLC). RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer has led to orphan-drug designation by the regulatory authorities in the USA and EU.;
DESCRIPTION Vandetanib is a Type-1 kinase inhibitor. It potently inhibits RET, VEGFR-2 (KDR) and EGFR tyrosine kinase activity . (GtoPdb)
DESCRIPTION Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure. (PKIDB)
DESCRIPTION inhibitor of VEGFR2 and EGFR (Informer Set)
DESCRIPTION Vandetanib hydrochloride is an anti-cancer drug that is used for the treatment of certain tumours of thethyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. (BOC Sciences Bioactive Compounds)
DESCRIPTION Vandetanib is an anti-cancer drug that is used for the treatment of certain tumours of thethyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. (BOC Sciences Bioactive Compounds)
Cell lines
11
Organisms
1
Compound Sets
31
AdooQ Bioactive Compound Library
A10963
Axon Medchem Screening Library
1411
BOC Sciences Bioactive Compounds
vandetanib-hydrochloride-cas-524722-52-9-item-84-463282
vandetanib-trifluoroacetate-cas-338992-53-3-item-84-463630
Cayman Chemical Bioactives
14706
28710
ChEMBL Approved Drugs
CHEMBL24828
ChEMBL Drugs
CHEMBL24828
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
5717
Drug Repurposing Hub
DrugBank
DB05294
DrugBank Approved Drugs
DB05294
DrugCentral
4178
DrugCentral Approved Drugs
4178
DrugMAP
DMRICNP
DrugMAP Approved Drugs
DMRICNP
Enamine BioReference Compounds
Guide to Pharmacology
5717
Informer Set
349002
Ki Database
ZD-6474
LINCS compound set
10198-101
10198-999
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL24828
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL24828
MedChem Express Bioactive Compound Library
HY-10260
NCATS Inxight Approved Drugs
YO460OQ37K
NIH Approved Oncology Drugs
NPC Screening Collection
Obsolete Compounds
vandetanib
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
Vandetanib
TargetMol Bioactive Compound Library
T1656
External IDs
52
Properties
(calculated by RDKit )
Molecular Weight
474.11
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
5.0
TPSA
59.51
Fraction CSP3
0.36
Chiral centers
0.0
Largest ring
6.0
QED
0.54
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
EGFR
KDR
VEGFR
Autophagy
VEGFR2
VEGFR3
EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA
VEGFR/EGFR inhibitor
VEGFA
PTK6
TEK
RET
Apoptosis related,Autophagy,EGFR,ROS,VEGFR
Compound status
FDA
Pathway
Protein Tyrosine Kinase/RTK
Angiogenesis
JAK/STAT Signaling
Tyrosine Kinase/Adaptors
Apoptosis
MOA
EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor
Indication
medullary thyroid cancer (MTC)
Therapeutic Class
Anticancer Agents
Source data